Studies addressing the direct effects of exogenous oxytocin on behavioural and/or metabolic outcomes in patients with craniopharyngioma are sparse, do not adhere to strict standards (e.g., randomization, double blinding, placebo-controlled) and mixed in methods (e.g., the length of treatment, dosage of intranasal oxytocin, and the outcomes measured) and participant characteristics, which impedes drawing any firm conclusions. This evidence concerns the gene OXT and craniopharyngioma.